Aktiesnakken — Marts 2010
-
med arzerra er der burn til plus 2 år
-
det er også mærkeligt at de ikke guider
-
så de sætter sig op til en opjustering i 1. kvartal
-
efter omstændighederne et ok regnskab med kontrol over omkostningerne. Der mangler dog guidance for de fremadrettede indtægter pga
-
et for usikkert patientmateriale at fremskrive på.
-
hej hya, det tror jeg du fejllæser fuldstændigt
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind